Gastroenterology
Volume 142, Issue 1 , Pages 140-151.e12, January 2012

Alterations in Lipid Metabolism Mediate Inflammation, Fibrosis, and Proliferation in a Mouse Model of Chronic Cholestatic Liver Injury

  • Tarek Moustafa

      Affiliations

    • Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    • Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
  • ,
  • Peter Fickert

      Affiliations

    • Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
  • ,
  • Christoph Magnes

      Affiliations

    • HEALTH - Institute for Biomedicine and Health Sciences, Joanneum Research, Graz, Austria
  • ,
  • Christian Guelly

      Affiliations

    • Center for Medical Research, Medical University of Graz, Graz, Austria
  • ,
  • Andrea Thueringer

      Affiliations

    • Institute of Pathology, Medical University of Graz, Graz, Austria
  • ,
  • Sasa Frank

      Affiliations

    • Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
  • ,
  • Dagmar Kratky

      Affiliations

    • Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
  • ,
  • Wolfgang Sattler

      Affiliations

    • Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
  • ,
  • Helga Reicher

      Affiliations

    • Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria
  • ,
  • Frank Sinner

      Affiliations

    • HEALTH - Institute for Biomedicine and Health Sciences, Joanneum Research, Graz, Austria
  • ,
  • Judith Gumhold

      Affiliations

    • Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
  • ,
  • Dagmar Silbert

      Affiliations

    • Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
  • ,
  • Günter Fauler

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
  • ,
  • Gerald Höfler

      Affiliations

    • Institute of Pathology, Medical University of Graz, Graz, Austria
  • ,
  • Achim Lass

      Affiliations

    • Institute of Molecular Biosciences, University of Graz, Graz, Austria
  • ,
  • Rudolf Zechner

      Affiliations

    • Institute of Molecular Biosciences, University of Graz, Graz, Austria
  • ,
  • Michael Trauner

      Affiliations

    • Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
    • Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    • Corresponding Author InformationReprint requests Address requests for reprints to: Michael Trauner, MD, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringerguertel 18-20, A-1090 Vienna, Austria

Received 31 January 2011; accepted 29 September 2011. published online 17 October 2011.

Background & Aims

The liver controls central processes of lipid and bile acid homeostasis. We aimed to investigate whether alterations in lipid metabolism contribute to the pathogenesis of chronic cholestatic liver disease in mice.

Methods

We used microarray and metabolic profiling analyses to identify alterations in systemic and hepatic lipid metabolism in mice with disruption of the gene ATP-binding cassette sub-family B member 4 (Abcb4−/− mice), a model of inflammation-induced cholestatic liver injury, fibrosis, and cancer.

Results

Alterations in Abcb4−/− mice, compared with wild-type mice, included deregulation of genes that control lipid synthesis, storage, and oxidation; decreased serum levels of cholesterol and phospholipids; and reduced hepatic long-chain fatty acyl-CoAs (LCA-CoA). Feeding Abcb4−/− mice the side chain–modified bile acid 24-norursodeoxycholic acid (norUDCA) reversed their liver injury and fibrosis, increased serum levels of lipids, lowered phospholipase and triglyceride hydrolase activities, and restored hepatic LCA-CoA and triglyceride levels. Additional genetic and nutritional studies indicated that lipid metabolism contributed to chronic cholestatic liver injury; crossing peroxisome proliferator-activated receptor (PPAR)-α–deficient mice with Abcb4−/− mice (to create double knockouts) or placing Abcb4−/− mice on a high-fat diet protected against liver injury, with features similar to those involved in the response to norUDCA. Placing pregnant Abcb4−/− mice on high-fat diets prevented liver injury in their offspring. However, fenofibrate, an activator of PPARα, aggravated liver injury in Abcb4−/− mice.

Conclusions

Alterations in lipid metabolism contribute to the pathogenesis and progression of cholestatic liver disease in mice.

Keywords:  Cholestasis , Canalicular Phospholipid Flippase , Hepatocellular Cancer , PSC

Abbreviations used in this paper:  AP, alkaline phosphatase, BA, bile acid, C/EBPα, CCAAT/enhancer binding protein α, CH, cholesterol, DAG, diacylglycerol, DKO, double knockout, FA, fatty acid, FFA, free fatty acid, HDL, high-density lipoprotein, HFD, high-fat diet, LCA-CoA, long-chain acyl-CoA ester, norUDCA, 24-norursodeoxycholic acid, PL, phospholipid, PPAR, peroxisome proliferator-activated receptor, TG, triglyceride, WT, wild-type

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Watch this article's video abstract and others at http://tiny.cc/j026c.

 Conflicts of interest The authors disclose the following: The Medical University Graz has filed a patent on the use of 24-norUDCA in chronic liver disease, and Michael Trauner and Peter Fickert are listed as coinventors. The remaining authors disclose no conflicts.

 Funding Supported by grants P19118 and the SFB-Lipotox F30 from the Austrian Science Fund.

PII: S0016-5085(11)01377-1

doi:10.1053/j.gastro.2011.09.051

Gastroenterology
Volume 142, Issue 1 , Pages 140-151.e12, January 2012